The leading antiviral treatments for a person with either a SARS-CoV-2 coronavirus infection or the disease it causes, COVID-19, became more accessible today.
The U.S. Food and Drug Administration (FDA) notified Pfizer Inc. and Merck Sharp & Dohme LLC on February 1, 2023, it has issued revised emergency Use Authorization (EAU) #105 and #108.
Read More
